Neurocrine confirms it is to acquire Soleno Therapeutics (SLNO) for USD 53/shr in cash or USD 2.9bln

Neurocrine's acquisition of Soleno Therapeutics for USD 53 per share highlights its strategic move to bolster its portfolio, with a total transaction value of USD 2.9 billion.

Newsquawk StaffPublished On the live feed at 7 more headlines followed before this page went public
Newsquawk headlinesUTC

IAEA says it can confirm the recent impact of military strikes near Iran's Bushehr nuclear facility, but has not been damaged by these strikes

US President Trump says that Iran has until Tuesday night to reopen the Strait of Hormuz, otherwise he would destroy all of Iran's bridges and power plants, according to the WSJ

Neurocrine confirms it is to acquire Soleno Therapeutics (SLNO) for USD 53/shr in cash or USD 2.9bln

Explosions heard from South Pars Petrochemical in Asalouye, via Fars

"Several explosions were heard from the American military headquarters in Jordan", via IRIB News

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This deal could signal confidence in revenue growth potential and may influence market perceptions regarding the health sector's M&A activity, potentially impacting peer valuations and investor sentiment in biotechnology.

Related headlines

The whole workspace, free to try.

Try it free